Rua Bioscience is trading at NZD 0.03, down 10.71%, with no clear company-specific catalyst identified for the October 6 decline. - October 6 reports described a UK sales agreement expected to generate more than NZ$10 million over two years and a partnership involving an indigenous cannabinoid-producing plant; neither linked these developments to the share-price fall. - The one-for-three rights offer at NZ$0.025 per share remains open as prior financing context, not a confirmed cause. The supplied sector indicator was down, while broader U.S. market context was positive.